IGC PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
IGC PHARMA, INC. (IGC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $0.25 per share for the 9-month period ending 2025-12-31, per its 10-KT filed 2026-03-18.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-03-18
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-06-30 was $0.00.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-06-30 was $1.39, a 49.46% increase year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2022-06-30 was $0.93, a 102.17% increase year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2021-06-30 was $0.46, a 15.00% increase year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $0.25.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $1.39, a 49.46% increase from fiscal 2022.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $0.93, a 102.17% increase from fiscal 2021.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2021 was $0.46, a 15.00% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.25 10-KT · filed 2026-03-18 | ||||
| 2025-09-30 | $0.64 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | ||||
| 2025-03-31 | $0.25 10-K · filed 2025-06-27 | ||||
| 2023-09-30 | $1.39 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $1.39 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $1.39 10-K · filed 2023-07-07 | ||||
| 2022-12-31 | $0.93 10-Q · filed 2023-02-14 | ||||
| 2022-09-30 | $0.93 10-Q · filed 2022-11-01 | ||||
| 2022-06-30 | $0.93 10-Q · filed 2022-08-05 | ||||
| 2022-03-31 | $0.93 10-K · filed 2023-07-07 | ||||
| 2021-12-31 | $0.85 10-Q · filed 2022-02-10 | ||||
| 2021-09-30 | $0.85 10-Q · filed 2021-10-29 | ||||
| 2021-06-30 | $0.46 10-Q · filed 2021-08-11 | ||||
| 2021-03-31 | $0.46 10-K · filed 2022-06-23 | ||||
| 2020-12-31 | $0.46 10-Q · filed 2021-02-16 | ||||
| 2020-09-30 | $0.46 10-Q · filed 2020-11-20 | ||||
| 2020-06-30 | $0.40 10-Q · filed 2020-08-19 | ||||
| 2020-03-31 | $0.40 10-K · filed 2021-06-14 | $0.40 10-K · filed 2020-07-13 | |||
| 2019-03-31 | $0.45 10-K · filed 2020-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |